StockData
Twist Bioscience Corp logo

Twist Bioscience Corp (TWST) stock

TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 16, 2026Score 13/30231% above fair value
$116.35+4.35 (+3.88%)

Close on Nov 18, 2026Market cap $7.30BP/E –Yield –

Earnings

Twist Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 1, 2027
Q1 FY2027 · estimated, before the open
Revenue, Q4 FY2026
$126.60M
+27.9% on a year earlier
EPS, Q4 FY2026
-$0.32
-$0.45 a year earlier
Latest guidance
Issued
Nov 12, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Twist Bioscience's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2027ended Dec 31, 2026Feb 1, 2027Expected––––
Q4 FY2026ended Sep 30, 2026Nov 12, 2026before the open$126.60M+27.9%-$0.32Release
Q3 FY2026ended Jun 30, 2026Aug 3, 2026before the open$118.40M+23.2%–Release
Q2 FY2026ended Mar 31, 2026May 4, 2026before the open$110.70M+19.3%–Release
Q1 FY2026ended Dec 31, 2025Feb 2, 2026before the open$103.70M+16.9%-$0.50Release
Q4 FY2025ended Sep 30, 2025Nov 14, 2025before the open$99.00M+16.9%-$0.45Release
Q3 FY2025ended Jun 30, 2025Aug 4, 2025before the open$96.10M+17.9%$0.33Release
Q2 FY2025ended Mar 31, 2025May 5, 2025before the open$92.80M+23.2%-$0.66Release
Q1 FY2025ended Dec 31, 2024Feb 3, 2025before the open$88.70M+24.1%-$0.53Release
Q4 FY2024ended Sep 30, 2024Nov 18, 2024before the open$84.70M+26.6%–Release
Q3 FY2024ended Jun 30, 2024Aug 2, 2024before the open$81.50M+27.9%-$1.47Release
Q2 FY2024ended Mar 31, 2024May 2, 2024after the close$75.30M+25.1%-$0.79Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Twist Bioscience's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$435.00M – $440.00M–NewFeb 2, 2026
G ross marginFY202652%–NewFeb 2, 2026
Total revenueQ1 FY2027$130.00M – $132.00M–NewNov 12, 2026
Total revenueFY2027$550.00M – $560.00M–NewNov 12, 2026
Gross marginFY202752.5% – 53%–NewNov 12, 2026
Capital expendituresFY2027$75.00M–NewNov 12, 2026

Guidance vs results

The last range Twist Bioscience gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2026Revenue$456.00M – $457.00M$459.40MΣ4QAbove range
FY2026Revenue growth+21%+21.99%Σ4QAbove range
Q4 FY2026Revenue$123.00M – $124.00M$126.60MAbove range
Q4 FY2026Revenue growth+25%+27.88%Above range
Q3 FY2026Revenue$114.00M – $115.00M$118.40MAbove range
Q3 FY2026Revenue growth+19%+23.2%Above range
Q2 FY2026Revenue$107.00M – $108.00M$110.70MAbove range
Q1 FY2026Revenue$100.00M – $101.00M$103.70MAbove range
Q1 FY2026Revenue growth+13% – +14%+16.91%Above range
FY2025Revenue$374.00M – $376.00M$376.60MΣ4QAbove range
Q4 FY2025Revenue$96.00M – $98.00M$99.00MAbove range
Q3 FY2025Revenue$94.00M – $97.00M$96.10MWithin range

Guidance history

Every forecast Twist Bioscience put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 12, 2026Capital expendituresFY2027$75.00MNew
Nov 12, 2026Gross marginFY202752.5% – 53%New
Nov 12, 2026Total revenueQ1 FY2027$130.00M – $132.00MNew
Nov 12, 2026Total revenueFY2027$550.00M – $560.00MNew
Aug 3, 2026growthFY2026+21%Raised
Aug 3, 2026Total revenueQ4 FY2026$123.00M – $124.00MNew
Aug 3, 2026growthQ4 FY2026+25%New
Aug 3, 2026Total revenueFY2026$456.00M – $457.00MRaised
May 4, 2026Gross marginFY202652%Reaffirmed
May 4, 2026growthFY2026+17% – +19%Raised
May 4, 2026Total revenueQ3 FY2026$114.00M – $115.00MNew
May 4, 2026Total revenueFY2026$442.00M – $447.00MRaised
May 4, 2026growthQ3 FY2026+19%New
Feb 2, 2026G ross marginFY202652%New
Feb 2, 2026Total revenueFY2026$435.00M – $440.00MNew
Feb 2, 2026T otal revenueQ2 FY2026$107.00M – $108.00MNew
Nov 14, 2025Gross marginFY202652%New
Nov 14, 2025DNA Synthesis and Protein Solutions (previously SynBio and Biopharma) revenue growthFY2026+15% – +18%Raised
Nov 14, 2025Total revenueQ1 FY2026$100.00M – $101.00MNew
Nov 14, 2025Total revenue growthQ1 FY2026+13% – +14%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Twist Bioscience filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?